DOI: 10.1002/ejoc.201402162



# Nucleophilic *gem*-Difluoro(phenylsulfanyl)methylation of Carbonyl Compounds with PhSCF<sub>2</sub>H in the Presence of a Phosphazene as a Base

## Teerachai Punirun,<sup>[a]</sup> Darunee Soorukram,<sup>\*[a]</sup> Chutima Kuhakarn,<sup>[a]</sup> Vichai Reutrakul,<sup>[a]</sup> and Manat Pohmakotr<sup>[a]</sup>

Keywords: Synthetic methods / Nucleophilic addition / Fluorine

Direct nucleophilic gem-difluoro(phenylsulfanyl)methylation of carbonyl compounds has been achieved by use of di-fluoro(phenylsulfanyl)methane (PhSCF<sub>2</sub>H) and the phosphazene base  $P_4$ -tBu in THF. Non-enolizable aldehydes and ketones are suitable substrates to undergo nucleophilic

## Introduction

Tremendous efforts are being directed towards the development of new methods for the introduction of fluorinecontaining groups into organic compounds, due to the enormous range of applications of fluorinated compounds in agrochemistry, pharmaceutical chemistry, and materials sciences.<sup>[1]</sup> Fluoride-induced nucleophilic fluoroalkylation with (fluoroalkyl)silanes (e.g., CF3TMS, the Rupert-Prakash reagent),<sup>[2]</sup> PhSO<sub>2</sub>CF<sub>2</sub>TMS,<sup>[3]</sup> and PhSCF<sub>2</sub>TMS is one of the most commonly used methods for the synthesis of fluorinated compounds. We and others have demonstrated the synthetic utility of PhSCF<sub>2</sub>TMS as a gem-difluoromethyl carbanion (PhSCF<sub>2</sub><sup>-</sup>) equivalent that can react with various electrophiles through initial activation by a fluoride ion.<sup>[4]</sup> Despite the successful results obtained with use of PhSCF<sub>2</sub>TMS as a difluoromethylating reagent, direct nucleophilic difluoromethylation with difluoro(phenylsulfanyl)methane (PhSCF<sub>2</sub>H, 1, readily available from thiophenol<sup>[5]</sup>) on treatment with a suitable base to generate PhSCF<sub>2</sub><sup>-</sup>, which acts as the true nucleophilic difluoroalkylating species, remains highly desirable. The challenge of such a transformation lies in the facile nature of  $\alpha$ -elimination of a fluoride ion from  $PhSCF_2^{-}$ . We had previously disclosed that PhSCF<sub>2</sub>MgBr, generated from PhSCF<sub>2</sub>Br through a bromine/magnesium exchange reaction, was highly unstable and rapidly underwent  $\alpha$ -elimination to give the corresponding carbenoid, which could be trapped with nucleophiles.<sup>[6]</sup> It has previously been reported that

[a] Center of Excellence for Innovation in Chemistry (PERCH-CIC) and Department of Chemistry, Faculty of Science, Mahidol University,
Rama VI Road, Bangkok 10400, Thailand
E-mail: darunce.soo@mahidol.ac.th
http://chemistry.sc.mahidol.ac.th
Supporting information for this article is available on the

Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/ejoc.201402162.

gem-difluoro(phenylsulfanyl)methylation, providing  $\alpha$ -gemdifluoromethylated adducts in good yields. In addition, this methodology is also applicable with cyclic imides and acid anhydrides.

sulfoxide- and sulfone-stabilized fluorinated carbanions – PhSOCHF<sup>-</sup>,<sup>[7]</sup> PhSOCF<sub>2</sub><sup>-</sup>,<sup>[8]</sup> and PhSO<sub>2</sub>CF<sub>2</sub><sup>-[9]</sup> – could be generated from their corresponding hydrofluorocarbon precursors. The preparation of PhSCF<sub>2</sub><sup>-</sup> from PhSCF<sub>2</sub>H (1) by employment of a base, such as *t*BuOK, KOH, or N(TMS)<sub>3</sub>/TMAF, in DMF was only recently disclosed by Hu and co-workers.<sup>[10,9c]</sup>

A phosphazene base –  $P_4$ -tBu, a strong non-metallic or Schwesinger base<sup>[11]</sup> – was introduced by Shibata and coworkers as an organo-superbase for the direct generation of a stable form of  $CF_3^-$  from  $CHF_3$  in  $THF_1^{[12]}$  Inspired by their finding and in continuation of our ongoing research into developing the synthetic methodology for the synthesis of fluorinated compounds, we have investigated the use of  $P_4$ -tBu as a base for the direct generation of  $PhSCF_2^-$  from 1 and its use for nucleophilic *gem*-difluoro(phenylsulfanyl)methylation of carbonyl compounds 2 (Scheme 1). Notably, *gem*-difluoromethylated adducts 3 are useful synthetic precursors that can be converted into various fluorinated com-



Scheme 1. Nucleophilic *gem*-difluoro(phenylsulfanyl)methylation of carbonyl compounds.

pounds, such as 1,1-difluoroalkenes, *gem*-difluoromethylenated cyclopentanols, and  $\alpha$ -*gem*-(difluoromethyl) alcohols. Syntheses of **3** through the fluoride-catalyzed nucleophilic addition of PhSCF<sub>2</sub>TMS to carbonyl compounds had previously been reported.<sup>[4b,4c]</sup>

### **Results and Discussion**

To begin with, the optimal reaction conditions for the generation of PhSCF<sub>2</sub><sup>-</sup> from 1 in the presence of P<sub>4</sub>-tBu as base were examined, together with its subsequent nucleophilic addition to 2-naphthaldehyde (2a). To our delight, it was initially found that upon addition of a solution of  $P_4$ -tBu (0.8 M in hexane, 1.5 equiv.) to a mixture of 1 (1.5 equiv.) and 2a in dry THF at -20 °C followed by further stirring at -20 °C for 1 h, the expected adduct 3a was obtained in 67% yield. Significant improvements in the yields were observed when the reaction was performed at elevated temperatures.  $P_4$ -tBu-mediated reactions between 1 and 2a carried out at 0 °C and at room temperature, each for 1 h, provided **3a** in 92% and 85% yields, respectively. Attempts to perform the reaction with use of a catalytic quantity of  $P_4$ -tBu (10 mol-%) were unsatisfactory; a low yield (34% yield) of 3a was obtained and a longer reaction time (7 h) was required.

With the optimized reaction conditions in hand, the scope of the carbonyl compounds was next examined. The results are summarized in Table 1. In most cases, aromatic aldehydes underwent the P4-tBu-induced direct nucleophilic addition of PhSCF<sub>2</sub><sup>-</sup> derived from 1 to provide the expected adducts 3 in good to high yields. Benzaldehyde (2b) and aromatic aldehydes 2c-2h, with either electron-donating or electron-withdrawing groups on their benzene rings, readily underwent the reaction to give the corresponding adducts **3b–3h** in 77–96% yields (Table 1, Entries 2–8). Benzophenone (2i) was also a good substrate, providing adduct 3i in high yield (Table 1, Entry 9). It is worth noting that the reaction was found to be sensitive to aldehyde or ketone substrates bearing enolizable *a*-protons. Under standard reaction conditions, 3-phenylpropanal and acetophenone failed to provide the expected products.

After having succeeded with non-enolizable carbonyl compounds as substrates, we then expanded the substrate scope to imide and acid anhydride substrates. Gratifyingly, the same treatment of symmetrical phthalimides **2j** and **2k** worked well and provided the corresponding adducts **3j** and **3k** in 92% and 74% yields, respectively (Table 1, Entries 10 and 11). Symmetrical acid anhydride **2l** gave **3l** in 94% yield (Table 1, Entry 12). Interestingly, high chemoselectivity (95:5) as determined by <sup>19</sup>F NMR was observed when unsymmetrical acid anhydride **2m** was employed as a substrate, leading to product **3m** in 75% yield (Table 1, Entry 13). It is worth mentioning that a fluoride-catalyzed nucleophilic addition of PhSCF<sub>2</sub>TMS to **2m** gave **3m** as a 1:1 mixture with its regioisomer.<sup>[4p]</sup>

At this point, the mechanism for the reactions between 1 and carbonyl compounds mediated by  $P_4$ -*t*Bu as base





[a] Reaction conditions:  $P_4$ -tBu (1.5 equiv.) was added to a mixture of **2** (0.1 mmol) and **1** (1.5 equiv.) in THF at 0 °C. [b] Isolated yields. [c] The ratio was determined by <sup>19</sup>F NMR spectroscopy.

should be addressed (Scheme 2). On the basis of relevant work reported by Shibata, it is proposed that deprotonation of **1** with  $P_4$ -*t*Bu base could lead to the formation of an ion pair of [PhSCF<sub>2</sub>]<sup>-</sup> and [ $P_4$ -*t*Bu/H]<sup>+</sup> (A).<sup>[12a]</sup> Unlike

# FULL PAPER

PhSCF<sub>2</sub>MgBr, which proved to be unstable and rapidly collapsed to yield PhSCF carbenoid,<sup>[6]</sup> the [PhSCF<sub>2</sub>]<sup>-</sup> component of **A** seems to be stable under the reaction conditions (0 °C in THF)<sup>[13]</sup> and readily reacted with various non-enolizable carbonyl compounds **2** to give the corresponding adducts **3** via alkoxide anions **B**. The exceptional stability of the [PhSCF<sub>2</sub>]<sup>-</sup> component of **A** is believed to be attributable to the destabilization of the ion pair of F<sup>-</sup> and [P<sub>4</sub>-*t*Bu/H]<sup>+</sup> (**C**) upon  $\alpha$ -elimination of **A**. In addition, formation of a sterically demanding [P<sub>4</sub>-*t*Bu/H]<sup>+</sup> counterion also prevents the  $\alpha$ -elimination process in the [PhSCF<sub>2</sub>]<sup>-</sup> part of **A**. The observed results emphasize the crucial roles of P<sub>4</sub>-*t*Bu as a base in a direct generation of the fluorinated carbanion from its corresponding hydrofluorocarbon.



Scheme 2. Proposed mechanism for the reactions between 1 and carbonyl compounds 2 mediated by  $P_4$ -*t*Bu base.

Encouraged by the above results, we next investigated the reactions of 1 with activated carbonyl compounds mediated by  $P_4$ -*t*Bu base (Table 2). To our surprise, treatment of 1 with chalcone (**2n**) in the presence of  $P_4$ -*t*Bu led to the formation of benzaldehyde adduct **3b** as major product (60% yield) and the expected adduct **3n** as a minor product (27% yield) (Table 2, Entry 1). An improved yield of **3n** (from 27% to 70% yield) was obtained when compound 1 and  $P_4$ -*t*Bu were premixed at 0 °C for 30 min prior to the addition of chalcone (**2n**, Table 2, Entry 2).

Cinnamaldehyde (20) did not give the expected product 30; benzaldehyde adduct 3b was obtained as a sole product in 95% yield (Table 2, Entry 3). The modified reaction sequence as for 2n was also applied to cinnamaldehyde (20). Unfortunately, adduct 3b was isolated in 80% yield as a sole product (Table 2, Entry 4).

Finally, 2-methoxycinnamaldehyde (2p) yielded the desired adduct **3p** in 53% yield together with the competing adduct **3p**' in 39% yield (Table 2, Entry 5).

Table 2. Reactions between 1 and  $\alpha$ , $\beta$ -unsaturated carbonyl compounds mediated by P<sub>4</sub>-*t*Bu.



[a] Reaction conditions:  $P_4$ -tBu (1.5 equiv.) was added to a mixture of **2** (0.1 mmol) and **1** (1.5 equiv.) in THF at 0 °C. [b] Isolated yields. [c] Compound **2** was added to a mixture of **1** and  $P_4$ -tBu in THF cooled to 0 °C.

From the results obtained, it is believed that the in situ generation of the aldehyde occurred under the standard reaction conditions. In order to confirm our hypothesis, chalcone (**2n**) was treated with  $P_4$ -*t*Bu (1.5 equiv.) in dry THF at 0 °C without addition of compound **1** (Scheme 3). After the reaction mixture had been allowed to stir for 10 min, TLC revealed that chalcone (**2n**) had been completely consumed and that newly formed spots had appeared. The formation of benzaldehyde was observed and confirmed by TLC and <sup>1</sup>H NMR analyses of the crude mixture. After purification of the crude mixture by preparative thin-layer chromatography, compounds **4**, **5**, and **6** were isolated in 5%, 7%, and 70% yields, respectively (see the Supporting Information).

On the basis of the observed control experiments, a plausible reaction mechanism for the reactions between PhSCF<sub>2</sub>H and  $\alpha$ , $\beta$ -unsaturated carbonyl compounds in the presence of P<sub>4</sub>-*t*Bu as a base was proposed (Scheme 4). It is believed that base-induced retro-aldol reactions of the substrates **2n**-**2p** took place and that the existence of trace amount of water played a crucial role. As a consequence, instead of 1,2-addition of [PhSCF<sub>2</sub>]<sup>-</sup> of **A** to, for example, **2n**, leading to the desired product **3n**, the substrate **2n** was attacked by the hydroxide ion in a conjugate fashion to give the intermediate **D**. The hydroxide ion should originate



Scheme 3. The reaction between chalcone 2n and  $P_4$ -tBu.



Scheme 4. Proposed mechanism for reactions between 1 and  $\alpha,\beta$ -unsaturated carbonyl compounds in the presence of P<sub>4</sub>-tBu.

from phosphazenium hydroxide,<sup>[14]</sup> which would be readily generated upon deprotonation of H<sub>2</sub>O (p $K_a = 15.7$  in water) with P<sub>4</sub>-tBu (p $K_b = 42.7$  in MeCN). Next, the intermediate **D** could either react with a second equivalent of **2n** or be protonated, leading to the observed compound **5** and the aldol adduct **4**. A base-induced retro-aldol reaction of **4** would provide the corresponding benzaldehyde and acetophenone. In the absence of **1**, the resulting acetophenone could undergo base-catalyzed conjugate addition to **2n** to yield the observed compound **6**. However, under the standard reaction conditions, the readily formed benzaldehyde could competitively react with the [PhSCF<sub>2</sub>]<sup>-</sup> component of **A** to give the observed product **3b**.

#### Conclusions

In conclusion, the direct generation of "naked PhSCF<sub>2</sub>-" from difluoro(phenylsulfanyl)methane (PhSCF<sub>2</sub>H) was achieved by using phosphazene (P<sub>4</sub>-*t*Bu) as a base. The generated PhSCF<sub>2</sub><sup>-</sup> is stable in THF at 0 °C and promptly reacted with various non-enolizable carbonyl compounds such as aromatic aldehydes and ketones, as well as with cyclic imides and acid anhydrides. This synthetic methodology proved potentially useful as a direct route to  $\alpha$ -gem-difluoromethylated adducts, which are useful synthetic precursors for further synthetic conversion into a variety of fluorinated compounds.

#### **Experimental Section**

**General:** All reactions were performed under argon. Glassware, needles, and syringes were oven-dried and then kept in a desiccator before use. THF was distilled from sodium/benzophenone ketyl. A solution of  $P_{4^-}tBu$  (0.8 M in hexane) was purchased from Sigma-

Aldrich. Preparative TLC plates were produced with Merck silica gel 60  $PF_{254}$  (Art 7747). Column chromatography was performed with Merck silica gel 60  $PF_{254}$  (Art 7734). Other common solvents [hexanes, ethyl acetate (EtOAc), and dichloromethane (CH<sub>2</sub>Cl<sub>2</sub>)] were distilled before use. The <sup>1</sup>H, <sup>13</sup>C, and <sup>19</sup>F NMR spectra were recorded in CDCl<sub>3</sub> with a Bruker 400 (400 MHz) spectrometer. Tetramethylsilane, CDCl<sub>3</sub>, and trichlorofluoromethane were used as internal standards in <sup>1</sup>H, <sup>13</sup>C, and <sup>19</sup>F NMR spectra, respectively. The IR spectra were recorded with an ALPHA FT-IR spectrometer. The mass spectra were recorded with a Thermo Finnigan Polaris Q mass spectrometer. The high-resolution mass spectra were recorded with an HR-TOF-MS Micromass model VQTOF2 mass spectrometer.

General Procedure A for the Synthesis of Compounds 3a–3m: A solution of P<sub>4</sub>-*t*Bu base (0.8 M in hexane, 190  $\mu$ L, 0.15 mmol, 1.5 equiv.) was added dropwise to a solution mixture of a compound **2** (0.1 mmol, 1 equiv.) and PhSCF<sub>2</sub>H (**1**, 24 mg, 0.15 mmol, 1.5 equiv.) in dry THF (0.5 mL), cooled to 0 °C. After having been stirred at 0 °C for 1 h, the reaction mixture was quenched with HCl (1 N) and then extracted with EtOAc (3 × 10 mL). The combined organic phase was washed with brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>.

**2,2-Difluoro-1-(naphthalen-2-yl)-2-(phenylsulfanyl)ethanol** (3a):<sup>[4b,4c,10]</sup> Treatment of 2-naphthaldehyde (2a, 16 mg, 0.1 mmol) with **1** (24 mg, 0.15 mmol) and P<sub>4</sub>-*t*Bu base (0.8 M in hexane, 190 µL, 0.15 mmol) as described in General Procedure A gave 3a (30 mg, 92%) as a white solid after column chromatography (SiO<sub>2</sub>, 10% EtOAc in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 7.86 (s, 1 H, Ar*H*), 7.81–7.70 (m, 3 H, Ar*H*), 7.53–7.47 (m, 3 H, Ar*H*), 7.47–7.37 (m, 2 H, Ar*H*), 7.35–7.28 (m, 1 H, Ar*H*), 7.28–7.20 (m, 2 H, Ar*H*), 5.08 (t, *J* = 9.4 Hz, 1 H, C*H*), 2.86 (s, 1 H, O*H*) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 136.5 (2 × CH), 133.7 (C), 132.9 (C), 132.6 (C), 129.9 (CH), 129.1 (2 × CH), 129.1 (t, *J* = 283.2 Hz, CF<sub>2</sub>), 128.3 (CH), 128.2 (CH), 127.8 (CH), 127.6 (CH), 126.6 (CH), 126.4 (CH), 125.8 (C), 125.0 (CH), 76.3 (t, *J* = 209.2, 7.7 Hz, 1 F), -84.2 (dd, *J* = 209.2, 11.7 Hz, 1 F) ppm.

# FULL PAPER

1-(Benzo[d][1,3]dioxol-5-yl)-2,2-difluoro-2-(phenylsulfanyl)ethanol (3c): Treatment of piperonaldehyde (2c, 16 mg, 0.1 mmol) with 1 (24 mg, 0.15 mmol) and P<sub>4</sub>-tBu base (0.8 M in hexane, 190  $\mu$ L, 0.15 mmol) as described in General Procedure A gave 3c (25 mg, 77%) as a pale yellow oil after column chromatography (SiO<sub>2</sub>, 10%EtOAc in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 7.50 (d, J = 7.7 Hz, 2 H, ArH), 7.37–7.30 (m, 1 H, ArH), 7.30–7.25 (m, 2 H, ArH), 6.92 (s, 1 H, ArH), 6.85 (d, J = 8.3 Hz, 1 H, ArH), 6.73 (d, J = 8.3 Hz, 1 H, ArH), 5.90 (s, 2 H, CH<sub>2</sub>), 4.83 (dd, J = 10.7, 8.3 Hz, 1 H, CH), 2.69 (br. s, 1 H, OH) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 148.3 (C), 147.8 (C), 136.4 (2× CH), 129.9 (CH), 129.1 (2 × CH), 128.9 (C), 128.8 (t, J = 283.2 Hz, CF<sub>2</sub>), 125.9 (C), 121.8 (CH), 108.1 (CH), 108.0 (CH), 101.3 (CH<sub>2</sub>), 76.0 (t, J = 26.6 Hz, CH) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta$  = -81.8 (d, J = 209.0 Hz, 1 F), -84.6 (dd, J = 209.0, 10.3 Hz, 1 F) ppm. IR  $(CDCl_3)$ :  $\tilde{v} = 3449, 1503, 1488, 1422, 1247, 1036, 923, 788,$ 748 cm<sup>-1</sup>. MS: m/z (%) = 310 (5) [M]<sup>+</sup>, 308 (35), 272 (33), 151 (100), 150 (58), 149 (40), 123 (32), 93 (28), 65 (44). HRMS (ESI-TOF): calcd. for  $C_{15}H_{12}F_2O_3SNa [M + Na]^+ 333.0373$ ; found 333.0365.

208.2 Hz, 1 F), -84.9 (dd, J = 208.2, 11.5 Hz, 1 F) ppm.

**2,2-Difluoro-2-(phenylsulfanyl)-1-(***p***-tolyl)ethanol (3d):**<sup>[4c,10]</sup> Treatment of *p*-tolualdehyde (**2d**, 13 mg, 0.1 mmol) with **1** (24 mg, 0.15 mmol) and P<sub>4</sub>-*t*Bu base (0.8 M in hexane, 190 µL, 0.15 mmol) as described in General Procedure A gave **3d** (24 mg, 79%) as a white solid after column chromatography (SiO<sub>2</sub>, 10% EtOAc in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 7.51 (d, *J* = 7.5 Hz, 2 H, Ar*H*), 7.38–7.22 (m, 5 H, Ar*H*), 7.13 (d, *J* = 7.5 Hz, 2 H, Ar*H*), 4.89 (t, *J* = 9.5 Hz, 1 H, C*H*), 2.63 (br. s, 1 H, O*H*), 2.69 (s, 3 H, C*H*<sub>3</sub>) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 131.9 (C), 136.5 (2× CH), 132.3 (C), 129.8 (CH), 129.1 (2× CH), 129.0 (2× CH), 128.9 (t, *J* = 283.1 Hz, CF<sub>2</sub>), 127.7 (2× CH), 125.9 (C), 76.1 (t, *J* = 26.5 Hz, CH), 21.3 (CH<sub>3</sub>) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta$  = -81.6 (d, *J* = 207.9 Hz, 1 F), -84.7 (dd, *J* = 207.9, 11.1 Hz, 1 F) ppm.

1-(2,4-Dimethoxyphenyl)-2,2-difluoro-2-(phenylsulfanyl)ethanol (3e):<sup>[4c]</sup> Treatment of 2,4-dimethoxybenzaldehyde (2e, 17 mg, 0.1 mmol) with 1 (24 mg, 0.15 mmol) and  $P_{4}\text{-}tBu$  base (0.8  $\mbox{m}$  in hexane, 190 µL, 0.15 mmol) as described in General Procedure A gave 3e (32 mg, 96%) as a white solid after column chromatography (SiO<sub>2</sub>, 10% EtOAc in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 7.53 (d, J = 6.9 Hz, 2 H, ArH), 7.37–7.19 (m, 4 H, ArH), 6.45 (dd, J = 8.5, 2.3 Hz, 1 H, ArH), 6.41 (d, J = 2.3 Hz, 1 H, ArH), 5.15 (dd, *J* = 12.8, 7.8 Hz, 1 H, C*H*), 3.77 (s, 3 H, OC*H*<sub>3</sub>), 3.75 (s, 3 H, OCH<sub>3</sub>), 3.47 (d, J = 7.2 Hz, 1 H, OH) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 161.4 (C), 158.8 (C), 136.4 (2× CH), 131.2 (CH), 130.4 (CH), 129.6 (t, J = 284.2 Hz, CF<sub>2</sub>), 128.9 (2× CH), 126.5 (C), 115.9 (C), 104.8 (CH), 99.0 (CH), 73.0 (t, J = 26.6 Hz, CH), 55.7 (CH<sub>3</sub>), 55.4 (CH<sub>3</sub>) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta$  = -81.5 (dd, J = 204.2, 8.1 Hz, 1 F), -84.4 (dd, J = 204.2, 12.2 Hz, 1 F) ppm.

**1-[4-(Dimethylamino)phenyl]-2,2-difluoro-2-(phenylsulfanyl)ethanol** (**3f**):<sup>[9]</sup> Treatment of 4-(dimethylamino)benzaldehyde (**2f**, 15 mg, 0.1 mmol) with **1** (24 mg, 0.15 mmol) and P<sub>4</sub>-*t*Bu base (0.8 M in hexane, 190 μL, 0.15 mmol) as described in General Procedure A gave **3f** (27 mg, 87%) as a brown oil after column chromatography (SiO<sub>2</sub>, 10% EtOAc in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 7.59 (d, *J* = 8.4 Hz, 2 H, Ar*H*), 7.45–7.30 (m, 5 H, Ar*H*), 6.74 (d, *J* = 8.4 Hz, 2 H, Ar*H*), 4.91 (t, *J* = 9.4 Hz, 1 H, C*H*), 2.97 (s, 6 H, 2× C*H*<sub>3</sub>), 2.57 (br. s, 1 H, O*H*) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 150.9 (C), 136.4 (2× CH), 130.1 (C), 129.7 (2× CH), 129.2 (t, *J* = 283.2 Hz, CF<sub>2</sub>), 129.0 (2× CH), 128.7 (2× CH<sub>3</sub>) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta$  = -82.2 (dd, *J* = 205.9, 5.8 Hz, 1 F), -84.1 (dd, *J* = 205.9, 8.1 Hz, 1 F) ppm.

**1-(4-Chlorophenyl)-2,2-difluoro-2-(phenylsulfanyl)ethanol (3g):**<sup>[4b,10]</sup> Treatment of *p*-chlorobenzaldehyde (**2g**, 15 mg, 0.1 mmol) with **1** (24 mg, 0.15 mmol) and P<sub>4</sub>-*t*Bu base (0.8 м in hexane, 190 μL, 0.15 mmol) as described in General Procedure A gave **3g** (29 mg, 90%) as a white solid after column chromatography (SiO<sub>2</sub>, 10% EtOAc in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 7.49 (d, *J* = 7.2 Hz, 2 H, Ar*H*), 7.39–7.22 (m, 7 H, Ar*H*), 4.89 (dd, *J* = 10.9, 7.7 Hz, 1 H, C*H*), 2.79 (br. s, 1 H, O*H*) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 136.5 (2 × CH), 135.1 (C), 133.6 (C), 130.0 (CH), 129.2 (4 × CH), 128.7 (t, *J* = 283.2 Hz, CF<sub>2</sub>), 128.6 (2 × CH), 125.5 (C), 75.5 (t, *J* = 26.9 Hz, CH) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta$  = -81.1 (dd, *J* = 210.6, 6.6 Hz, 1 F), -85.2 (dd, *J* = 210.6, 9.6 Hz, 1 F) ppm.

**2,2-Difluoro-1-(furan-2-yl)-2-(phenylsulfanyl)ethanol (3h)**:<sup>[4c]</sup> Treatment of 2-furaldehyde (**2h**, 10 mg, 0.1 mmol) with **1** (24 mg, 0.15 mmol) and P<sub>4</sub>-*t*Bu base (0.8 M in hexane, 190 µL, 0.15 mmol) as described in General Procedure A gave **3h** (21 mg, 79%) as a brown oil after column chromatography (SiO<sub>2</sub>, 10% EtOAc in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 7.54 (d, J = 7.1 Hz, 2 H, Ar*H*), 7.44–7.26 (m, 4 H, Ar*H*), 6.45 (d, J = 3.3 Hz, 1 H, Ar*H*), 6.35 (dd, J = 3.3, 1.8 Hz, 1 H, Ar*H*), 4.94 (dd, J = 16.4, 8.7 Hz, 1 H, C*H*), 2.71 (d, J = 7.0 Hz, 1 H, O*H*) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 148.5 (C), 143.3 (CH), 136.6 (2× CH), 130.1 (CH), 129.2 (2× CH), 127.9 (t, J = 283.6 Hz, CF<sub>2</sub>), 125.6 (C), 110.7 (CH), 110.1 (CH), 70.6 (t, J = 28.1 Hz, CH) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta$  = –83.1 (dd, J = 207.2, 8.1 Hz, 1 F), –84.6 (dd, J = 207.2, 9.0 Hz, 1 F) ppm.

**2,2-Difluoro-1,1-diphenyl-2-(phenylsulfanyl)ethanol (3i):**<sup>[4b,4c,10]</sup> Treatment of benzophenone (**2i**, 19 mg, 0.1 mmol) with **1** (24 mg, 0.15 mmol) and P<sub>4</sub>-*t*Bu base (0.8 M in hexane, 190 µL, 0.15 mmol) as described in General Procedure A gave **3i** (34 mg, 95%) as a colorless solid after column chromatography (SiO<sub>2</sub>, 10% EtOAc in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 7.57–7.51 (m, 4 H, Ar*H*), 7.50–7.45 (m, 2 H, Ar*H*), 7.34–7.19 (m, 9 H, Ar*H*), 3.06 (s, 1 H, O*H*) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 140.3 (2 × C), 136.7 (2 × CH), 131.2 (t, *J* = 291.2 Hz, CF<sub>2</sub>), 129.8 (CH), 129.0 (2 × CH), 128.3 (3 × CH), 128.0 (4 × CH), 127.8 (3 × CH), 126.4 (C), 81.7 (t, *J* = 22.7 Hz, C) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta$  = –77.3 (s, 2 F) ppm.

**2-(E)-Cinnamyl-3-[difluoro(phenylsulfanyl)methyl]-3-hydroxyisoindolin-1-one (3j):**<sup>[4n]</sup> Treatment of **2j** (27 mg, 0.1 mmol) with **1** (24 mg, 0.15 mmol) and P<sub>4</sub>-*t*Bu base (0.8 M in hexane, 190 µL, 0.15 mmol) in dry THF (0.5 mL) at 0 °C as described in General Procedure A gave **3j** (40 mg, 92%) as a white solid after column chromatography (SiO<sub>2</sub>, 25% EtOAc in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 7.66 (t, *J* = 7.4 Hz, 2 H, Ar*H*), 7.53–7.41 (m, 2 H, Ar*H*), 7.33–7.22 (m, 5 H, Ar*H*), 7.21–7.09 (m, 5 H, Ar*H*), 6.53 (d, *J* = 15.9 Hz, 1 H, C*H*), 6.26 (dt, *J* = 15.9, 6.6 Hz, 1 H,



CH), 4.38 (dd, J = 15.6, 6.6 Hz, 1 H, CHH), 4.31 (s, 1 H, OH), 4.00 (dd, J = 15.6, 6.6 Hz, 1 H, CHH) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta = 168.1$  (C), 142.1 (C), 136.7 (2 × CH), 136.6 (C), 133.1 (CH), 132.7 (CH), 131.6 (2 × C), 130.9 (CH), 130.1 (CH), 129.0 (2 × CH), 128.5 (2 × CH), 128.5 (t, J = 290.3 Hz, CF<sub>2</sub>), 127.7 (CH), 126.5 (2 × CH), 124.9 (CH), 124.2 (CH), 123.6 (CH), 91.0 (t, J = 25.7 Hz, C), 42.1 (CH<sub>2</sub>) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta = -80.6$  (d, J = 210.6 Hz, 1 F), -82.6 (d, J = 210.6 Hz, 1 F) ppm.

2-Allyl-3-[difluoro(phenylsulfanyl)methyl]-3-hydroxyisoindolin-1-one (3k):<sup>[4n]</sup> Treatment of 2k (19 mg, 0.1 mmol) with 1 (24 mg, 0.15 mmol) and  $P_4$ -tBu base (0.8 M in hexane, 190 µL, 0.15 mmol) as described in General Procedure A gave 3k (26 mg, 74%) as a white solid after column chromatography (SiO<sub>2</sub>, 25% EtOAc in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 7.85–7.77 (m, 1 H, ArH), 7.75-7.69 (m, 1 H, ArH), 7.64-7.54 (m, 2 H, ArH), 7.46-7.37 (m, 3 H, ArH), 7.36-7.29 (m, 2 H, ArH), 6.08-6.59 (m, 1 H, *CH*), 5.35 (d, *J* = 17.1 Hz, 1 H, *CH*H), 5.22 (dd, *J* = 10.2, 1.2 Hz, 1 H, CH*H*), 4.47 (dd, *J* = 15.8, 5.3 Hz, 1 H, C*H*H), 3.96 (dd, *J* = 15.8, 7.1 Hz, 1 H, CHH), 3.80 (s, 1 H, OH) ppm. <sup>13</sup>C NMR  $(100 \text{ MHz}, \text{ CDCl}_3)$ :  $\delta = 167.8 \text{ (C)}, 141.8 \text{ (C)}, 136.7 \text{ (CH)}, 133.8$ (CH), 132.7 (CH), 131.6 (C), 131.0 (CH), 130.1 (CH), 129.1 (2× CH), 128.5 (t, J = 290.2 Hz, CF<sub>2</sub>), 124.9 (C), 124.1 (CH), 124.0 (CH), 123.7 (CH), 118.1 (CH<sub>2</sub>), 91.1 (t, J = 25.5 Hz, C), 42.6 (CH<sub>2</sub>) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta$  = -80.6 (d, J = 211.9 Hz, 1 F), -82.3 (d, J = 211.9 Hz, 1 F) ppm.

**3-[Difluoro(phenylsulfanyl)methyl]-3-hydroxyisobenzofuran-1(3H)one (31):**<sup>[4p]</sup> Treatment of **21** (15 mg, 0.1 mmol) with **1** (24 mg, 0.15 mmol) and P<sub>4</sub>-*t*Bu base (0.8 M in hexane, 190 µL, 0.15 mmol) as described in General Procedure A gave **31** (29 mg, 94%) as a white solid after column chromatography (SiO<sub>2</sub>, 20% EtOAc in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 7.91 (d, *J* = 7.5 Hz, 1 H, Ar*H*), 7.78–7.63 (m, 3 H, Ar*H*), 7.57 (d, *J* = 7.2 Hz, 2 H, Ar*H*), 7.46–7.41 (m, 1 H, Ar*H*), 7.40–7.34 (m, 2 H, Ar*H*), 4.96 (br., 1 H, O*H*) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 167.0 (C), 143.0 (2× C), 136.8 (2× CH), 134.9 (CH), 131.9 (CH), 130.4 (CH), 129.2 (2× CH), 127.4 (C), 126.3 (t, *J* = 287.3 Hz, CF<sub>2</sub>), 125.8 (CH), 124.5 (CH), 103.0 (t, *J* = 30.7 Hz, C) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta$  = -84.6 (d, *J* = 214.3 Hz, 1 F), -86.9 (d, *J* = 214.3 Hz, 1 F) ppm.

**3-[Difluoro(phenylsulfanyl)methyl]-3-hydroxy-5-methylisobenzofuran-1(3H)-one (3m):**<sup>[4p]</sup> Treatment of **2m** (16 mg, 0.1 mmol) with **1** (24 mg, 0.15 mmol) and P<sub>4</sub>-*t*Bu base (0.8 M in hexane, 190 µL, 0.15 mmol) as described in General Procedure A gave **3m** (24 mg, 75%), with a 95:5 ratio of the isomers as determined by <sup>19</sup>F NMR, as a colorless solid after column chromatography (SiO<sub>2</sub>, 15% EtOAc in hexanes). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 7.71 (d, *J* = 7.8 Hz, 1 H, Ar*H*), 7.49 (d, *J* = 7.3 Hz, 2 H, Ar*H*), 7.44 (s, 1 H, Ar*H*), 7.40–7.33 (m, 2 H, Ar*H*), 7.32–7.25 (m, 2 H, Ar*H*), 4.76 (br., 1 H, O*H*), 2.41 (s, 3 H, C*H*<sub>3</sub>) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 167.0 (C), 146.5 (C), 143.4 (C), 136.8 (2× CH), 132.9 (CH), 130.3 (CH), 129.1 (2× CH), 126.4 (t, *J* = 287.3 Hz, CF<sub>2</sub>), 125.4 (CH), 124.8 (CH), 124.7 (C), 124.6 (C), 102.8 (t, *J* = 30.5 Hz, C), 22.1 (CH<sub>3</sub>) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta$  = -84.5 (d, *J* = 213.8 Hz, 1 F), –87.1 (d, *J* = 213.8 Hz, 1 F) ppm.

General Procedure B for Reactions between  $1/P_4$ -*t*Bu and α,β-Unsaturated Carbonyl Compounds:  $P_4$ -*t*Bu base (0.8 M in hexane, 190 µL, 0.15 mmol, 1.5 equiv.) was added dropwise to a solution of **1** (24 mg, 0.15 mmol, 1.5 equiv.) in dry THF (0.2 mL), cooled to 0 °C. The reaction mixture was allowed to stir for 30 min, and then a solution of an α,β-unsaturated carbonyl compound **2** (0.1 mmol, 1.0 equiv.) in dry THF (0.3 mL) was added dropwise at 0 °C. After the complete consumption of **2** (1 h), the reaction mixture was quenched with HCl (1 N) and then extracted with EtOAc ( $3 \times 10 \text{ mL}$ ). The combined organic phase was washed with brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>.

(*E*)-1,1-Difluoro-2,4-diphenyl-1-(phenylsulfanyl)but-3-en-2-ol (3n): Treatment of chalcone (2n, 21 mg, 0.1 mmol) with 1 (24 mg, 0.15 mmol) and P<sub>4</sub>-tBu base (0.8  $\mu$  in hexane, 190  $\mu$ L, 0.15 mmol) as described in General Procedure B gave 3n as a pale yellow oil (26 mg, 70%) and **3b** (5 mg, 18%) after column chromatography (SiO<sub>2</sub>, 5% EtOAc in hexanes). **3n:** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ = 7.62 (d, J = 7.2 Hz, 2 H, ArH), 7.49 (d, J = 7.0 Hz, 2 H, ArH), 7.37-7.16 (m, 11 H, ArH), 6.84 (d, J = 16.0 Hz, 1 H, CH), 6.79 (d, J = 16.0 Hz, 1 H, CH), 2.84 (s, 1 H, OH) ppm. <sup>13</sup>C NMR  $(100 \text{ MHz}, \text{CDCl}_3): \delta = 138.6 \text{ (C)}, 136.6 \text{ (}2 \times \text{CH)}, 136.0 \text{ (C)}, 132.5 \text{ (}100 \text{ MHz}, \text{CDCl}_3): \delta = 138.6 \text{ (C)}, 136.6 \text{ (}2 \times \text{CH)}, 136.0 \text{ (C)}, 132.5 \text{ (}100 \text{ MHz}, \text{CDCl}_3): \delta = 138.6 \text{ (C)}, 136.6 \text{ (}2 \times \text{CH)}, 136.0 \text{ (C)}, 132.5 \text{ (}100 \text{ MHz}, \text{CDCl}_3): \delta = 138.6 \text{ (C)}, 136.6 \text{ (}2 \times \text{CH)}, 136.0 \text{ (C)}, 132.5 \text{ (}100 \text{ MHz}, \text{CDCl}_3): \delta = 138.6 \text{ (C)}, 136.6 \text{ (}2 \times \text{CH)}, 136.0 \text{ (C)}, 132.5 \text{ (}100 \text{ MHz}, \text{CDCl}_3): \delta = 138.6 \text{ (C)}, 136.6 \text{ (}2 \times \text{CH)}, 136.0 \text{ (C)}, 132.5 \text{ (}100 \text{ MHz}, \text{CDCl}_3): \delta = 138.6 \text{ (C)}, 136.6 \text{ (}2 \times \text{CH)}, 136.0 \text{ (C)}, 132.5 \text{ (}100 \text{ MHz}, \text{CDCl}_3): \delta = 138.6 \text{ (C)}, 136.6 \text{ (}100 \text{ MHz}, \text{CDCl}_3): \delta = 138.6 \text{ (}100 \text{ MHz}, \text{CD$ (CH), 130.5 (t, J = 289.6 Hz, CF<sub>2</sub>), 129.8 (CH), 129.0 (2×CH), 128.7 (2× CH), 128.4 (CH), 128.3 (CH), 128.1 (2× CH), 128.0 (CH), 127.9 (CH), 127.1 (CH), 126.9 (2× CH), 126.1 (C), 73.6 (t, J = 23.7 Hz, C) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta = -81.3$  (d, J = 205.7 Hz, 1 F), -82.1 (d, J = 205.7 Hz, 1 F) ppm. IR (CDCl<sub>3</sub>):  $\tilde{v} = 3461, 1449, 1265, 1059, 971, 744 \text{ cm}^{-1}$ . MS: m/z (%) = 368 (1)  $[M]^+$ , 327 (11), 209 (100), 191 (25), 131 (40), 103 (47), 77 (29). HRMS (ESI-TOF): calcd. for  $C_{22}H_{18}F_2OSNa [M + Na]^+ 391.0944$ ; found 391.0933.

Treatment of **2n** (21 mg, 0.1 mmol) with **1** (24 mg, 0.15 mmol) and  $P_4$ -*t*Bu base (0.8 M in hexane, 190 µL, 0.15 mmol) as described in General Procedure A gave **3n** (10 mg, 27%) and **3b** (16 mg, 60%).

(*E*)-1,1-Difluoro-4-(2-methoxyphenyl)-1-(phenylsulfanyl)but-3-en-2ol (3p)<sup>[4e]</sup> and 2,2-Difluoro-1-(2-methoxyphenyl)-2-(phenylsulfanyl)ethanol (3p'): Treatment of 2-methoxycinnamaldehyde (2p, 17 mg, 0.1 mmol) with 1 (24 mg, 0.15 mmol) and P<sub>4</sub>-*t*Bu base (0.8 M in hexane, 190  $\mu$ L, 0.15 mmol) as described in General Procedure A gave 3p as a pale yellow oil (18 mg, 53%) and 3p' (12 mg, 39%) after column chromatography (SiO<sub>2</sub>, 10% EtOAc in hexanes).

**Compound 3p:** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 7.57 (d, *J* = 7.6 Hz, 2 H, Ar*H*), 7.38–7.21 (m, 4 H, Ar*H*), 7.25–7.16 (m, 1 H, Ar*H*), 7.07 (d, *J* = 16.1 Hz, 1 H, C*H*), 6.88 (t, *J* = 7.4 Hz, 1 H, Ar*H*), 6.82 (d, *J* = 8.2 Hz, 1 H, Ar*H*), 6.23 (dd, *J* = 16.1, 6.6 Hz, 1 H, C*H*), 4.54 (br., 1 H, C*H*), 3.80 (s, 3 H, C*H*<sub>3</sub>), 2.33 (d, *J* = 5.2 Hz, 1 H, O*H*) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 157.1 (C), 136.6 (2× CH), 130.5 (CH), 129.9 (CH), 129.6 (CH), 129.1 (2× CH), 129.0 (t, *J* = 281.6 Hz, CF<sub>2</sub>), 127.4 (CH), 125.9 (C), 124.8 (C), 122.9 (CH), 120.7 (CH), 110.9 (CH), 75.6 (t, *J* = 26.8 Hz, CH), 55.5 (CH<sub>3</sub>) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta$  = -82.9 (dd, *J* = 209.8, 7.7 Hz, 1 F), -84.7 (dd, *J* = 209.8, 8.1 Hz, 1 F) ppm.

**Compound 3p':** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 7.54 (d, *J* = 6.9 Hz, 2 H, Ar*H*), 7.38–7.21 (m, 5 H, Ar*H*), 6.94 (dt, *J* = 7.5, 0.8 Hz, 1 H, Ar*H*), 6.87 (d, *J* = 8.3 Hz, 1 H, Ar*H*), 5.27–5.12 (m, 1 H, C*H*), 3.81 (s, 3 H, C*H*<sub>3</sub>), 3.71 (d, *J* = 7.9 Hz, 1 H, O*H*) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 157.7 (C), 136.4 (2×CH), 130.2 (CH), 129.8 (CH), 129.7 (CH), 129.3 (t, *J* = 287.7 Hz, CF<sub>2</sub>), 128.9 (2×CH), 126.4 (C), 123.3 (C), 120.9 (CH), 111.3 (CH), 73.6 (t, *J* = 26.7 Hz, CH), 55.7 (CH<sub>3</sub>) ppm. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>):  $\delta$  = -81.1 (dd, *J* = 205.4, 8.1 Hz, 1 F), -84.8 (dd, *J* = 205.4, 13.5 Hz, 1 F) ppm. IR (CDCl<sub>3</sub>):  $\hat{v}$  = 3474, 1602, 1493, 1463, 1439, 1245, 1047, 1024, 981, 963, 733 cm<sup>-1</sup>. MS: *m/z* (%) = 297 (1) [M + H]<sup>+</sup>, 259 (92), 137 (100), 107 (95), 77 (45). HRMS (ESI-TOF): calcd. for C<sub>15</sub>H<sub>14</sub>F<sub>2</sub>O<sub>2</sub>SNa [M + Na]<sup>+</sup> 319.0580; found 319.0574.

**Reaction of Chalcone (2n) with**  $P_4$ **-***t***Bu Base:** A solution of  $P_4$ -*t***Bu** base (0.8 M in hexane, 0.95 mL, 0.75 mmol, 1.5 equiv.) was added dropwise to a solution of compound **2n** (104 mg, 0.5 mmol, 1 equiv.) in dry THF (2.5 mL), cooled to 0 °C. After having been stirred at 0 °C for 10 min, the reaction mixture was quenched with

# FULL PAPER

HCl (1 N) and then extracted with EtOAc ( $3 \times 25$  mL). The combined organic phase was washed with brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>. The crude mixture was purified by preparative thinlayer chromatography (SiO<sub>2</sub>, 50% CH<sub>2</sub>Cl<sub>2</sub> in hexanes, multiple runs) to provide compounds **4**, **5**, and **6**.

**Compound 4:** This compound was obtained as a pale yellow oil (6 mg, 5%): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 7.93–7.85 (m, 2 H, Ar*H*), 7.56–7.47 (m, 1 H, Ar*H*), 7.44–7.35 (m, 4 H, Ar*H*), 7.34–7.28 (m, 2 H, Ar*H*), 7.27–7.20 (m, 1 H, Ar*H*), 5.29 (t, *J* = 6.0 Hz, 1 H, C*H*), 3.52 (s, 1 H, O*H*), 3.31 (d, *J* = 6.0 Hz, 2 H, C*H*<sub>2</sub>) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 200.2 (C), 142.9 (C), 136.6 (C), 133.7 (CH), 128.7 (2 × CH), 128.6 (2 × CH), 128.2 (2 × CH), 127.7 (CH), 125.7 (2 × CH), 70.0 (CH), 47.4 (CH<sub>2</sub>) ppm.

**Compound 5:** This compound was obtained as a white solid (7 mg, 7%): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 7.65–7.59 (m, 2 H, Ar*H*), 7.33–7.22 (m, 5 H, Ar*H*), 7.21–7.00 (m, 11 H, Ar*H*), 6.99–6.92 (m, 2 H, Ar*H*), 5.61 (d, *J* = 2.2 Hz, 1 H, C*H*), 5.22 (d, *J* = 10.0 Hz, 1 H, C*H*), 4.32 (dd, *J* = 10.0, 2.2 Hz, 1 H, C*H*), 3.89 (dd, *J* = 10.0, 10.0 Hz, 1 H, C*H*) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 202.9 (C), 152.2 (C), 142.7 (C), 138.4 (C), 138.3 (C), 135.0 (C), 132.3 (CH), 128.7 (2 × CH), 128.4 (CH), 128.2 (5 × CH), 127.8 (2 × CH), 127.7 (2 × CH), 127.5 (2 × CH), 127.3 (2 × CH), 127.0 (CH), 124.8 (2 × CH), 101.8 (CH), 80.9 (CH), 56.1 (CH), 44.9 (CH) ppm. HRMS (ESI-TOF): calcd. for C<sub>30</sub>H<sub>24</sub>O<sub>2</sub>Na [M + Na]<sup>+</sup> 439.1674; found 439.1672.

**Compound 6:**<sup>(15)</sup> This compound was obtained as a colorless oil (57 mg, 70%): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 7.88 (d, *J* = 7.9 Hz, 4 H, Ar*H*), 7.48 (t, *J* = 7.4 Hz, 2 H, Ar*H*), 7.42–7.33 (m, 4 H, Ar*H*), 7.27–7.17 (m, 4 H, Ar*H*), 7.16–7.07 (m, 1 H, Ar*H*), 4.00 (quin, *J* = 7.0 Hz, 1 H, C*H*), 3.43 (dd, *J* = 16.7, 7.0 Hz, 2 H, C*H*<sub>2</sub>), 3.29 (dd, *J* = 16.7, 7.0 Hz, 2 H, C*H*<sub>2</sub>) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 198.6 (2× C), 143.8 (C), 136.9 (2× C), 133.1 (2× CH), 128.6 (2× CH), 128.5 (4× CH), 128.1 (4× CH), 127.5 (2× CH), 126.7 (CH), 44.9 (2× CH<sub>2</sub>), 37.2 (CH) ppm.

**Supporting Information** (see footnote on the first page of this article): Copies of <sup>1</sup>H, <sup>13</sup>C, and <sup>19</sup>F NMR spectra for all reported compounds.

## Acknowledgments

The authors acknowledge financial support from the Office of the Higher Education Commission and Mahidol University under the National Research Universities Initiative, the Thailand Research Fund through the Royal Golden Jubilee Ph.D. Program (grant number PHD/0121/2554, grants to T. P. and M. P.), and from the Center of Excellence for Innovation in Chemistry (PERCH-CIC).

G. K. S. Prakash, A. K. Yudin, Chem. Rev. 1997, 97, 757-786; e) S. Mizuta, N. Shibata, T. Sato, H. Fujimoto, S. Nakamura, T. Toru, Synlett 2006, 267-270; f) T. Billard, B. R. Langlois, Eur. J. Org. Chem. 2007, 891-897; g) E. J. Cho, T. D. Senecal, T. Kinzel, Y. Zhang, D. A. Watson, S. L. Buchwald, Science 2010, 328, 1679-1681; h) L. Chu, F.-L. Qing, Org. Lett. 2010, 12, 5060-5063; i) T. D. Senecal, A. T. Parsons, S. L. Buchwald, J. Org. Chem. 2011, 76, 1174-1176; j) F. Wang, T. Luo, J. Hu, Y. Wang, H. S. Krishnan, P. V. Jog, S. K. Ganesh, G. K. S. Prakash, G. A. Olah, Angew. Chem. Int. Ed. 2011, 50, 7153-7157; Angew. Chem. 2011, 123, 7291; k) X. Jiang, L. Chu, F.-L. Qing, J. Org. Chem. 2012, 77, 1251-1257; l) X. Wu, L. Chu, F.-L. Qing, Tetrahedron Lett. 2013, 54, 249-251; m) E. Obijalska, G. Mlostoń, G. Utecht, H. Heimgartner, J. Fluorine Chem. 2013, 151, 7-11; n) J. Gawronski, N. Wascinska, J. Gajewy, Chem. Rev. 2008, 108, 5227-5252; o) H. Kawai, K. Tachi, E. Tokunaga, M. Shiro, N. Shibata, Org. Lett. 2010, 12, 5104-5107; p) C. Masusai, D. Soorukram, C. Kuhakarn, P. Tuchinda, C. Pakawatchai, S. Saithong, V. Reutrakul, M. Pohmakotr, Org. Biomol. Chem. 2013, 11, 6650-6658; q) C. Masusai, D. Soorukram, C. Kuhakarn, P. Tuchinda, V. Reutrakul, M. Pohmakotr, J. Fluorine Chem. 2013, 154, 37-42; r) J.-A. Ma, D. Cahard, Chem. Rev. 2004, 104, 6119-6146; s) A. D. Dilman, V. V. Levin, Eur. J. Org. Chem. 2011, 831-841; t) M. Liu, J. Li, X. Xiao, Y. Xie, Y. Shi, Chem. Commun. 2013, 49, 1404-1406; u) A. Hoffman-Röder, P. Seiler, F. Diederich, Org. Biomol. Chem. 2004, 2, 2267-2269; v) Y. Wu, L. Deng, J. Am. Chem. Soc. 2012, 134, 14334-14337; w) S. Barata-Vallejo, M. R. Torviso, B. Lantaño, S. M. Bonesi, A. Postigo, J. Fluorine Chem. 2014, http://dx.doi.org/10.1016/j.jfluchem.2014.01.016.

- [3] a) G. K. S. Prakash, J. Hu, G. A. Olah, J. Org. Chem. 2003, 68, 4457–4463; b) C. Ni, J. Hu, Tetrahedron Lett. 2005, 46, 8273–8277; c) W. Huang, C. Ni, Y. Zhao, B. Gao, J. Hu, J. Fluorine Chem. 2012, 143, 161–166; d) J. Liu, C. Ni, F. Wang, J. Hu, Tetrahedron Lett. 2008, 49, 1605–1608; e) L. Zhu, Y. Li, Y. Zhao, J. Hu, Tetrahedron Lett. 2010, 51, 6150–6152; f) V. V. Levin, P. K. Elkin, M. I. Struchkova, A. D. Dilman, J. Fluorine Chem. 2013, 154, 43–46; g) J. Zhu, F. Wang, W. Huang, Y. Zhao, W. Ye, J. Hu, Synlett 2011, 899–902.
- [4] a) G. K. S. Prakash, J. Hu, Acc. Chem. Res. 2007, 40, 921-930 and references cited; b) G. K. S. Prakash, J. Hu, Y. Wang, G. A. Olah, J. Fluorine Chem. 2005, 126, 529-534; c) M. Pohmakotr, K. Boonkitpattarakul, W. Ieawsuwan, S. Jarussophon, N. Duangdee, P. Tuchinda, V. Reutrakul, Tetrahedron 2006, 62, 5973-5985; d) S. Mizuta, N. Shibata, S. Ogawa, H. Fujimoto, S. Nakamura, T. Toru, Chem. Commun. 2006, 2575-2577; e) K. Boonkitpattarakul, D. Soorukram, P. Tuchinda, V. Reutrakul, M. Pohmakotr, J. Fluorine Chem. 2011, 132, 987-990; f) W. Thaharn, D. Soorukram, C. Kuhakarn, P. Tuchinda, V. Reutrakul, M. Pohmakotr, Angew. Chem. Int. Ed. 2014, 53, 2212-2215; g) M. Pohmakotr, D. Panichakul, P. Tuchinda, V. Reutrakul, Tetrahedron 2007, 63, 9429-9436; h) T. Punirun, K. Peewasan, C. Kuhakarn, D. Soorukram, P. Tuchinda, V. Reutrakul, P. Kongsaeree, S. Prabpai, M. Pohmakotr, Org. Lett. 2012, 14, 1820-1823; i) Y. Li, J. Hu, Angew. Chem. Int. Ed. 2005, 44, 5882-5886; Angew. Chem. 2005, 117, 6032; j) Y. Li, J. Hu, Angew. Chem. Int. Ed. 2007, 46, 2489-2492; Angew. Chem. 2007, 119, 2541; k) M. D. Kosobokov, A. D. Dilman, M. I. Struchkova, P. A. Belyakov, J. Hu, J. Org. Chem. 2012, 77, 2080-2086; 1) W. Huang, C. Ni, Y. Zhao, W. Zhang, A. D. Dilman, J. Hu, Tetrahedron 2012, 68, 5137-5144; m) Y. Li, J. Hu, J. Fluorine Chem. 2008, 129, 382-385; n) T. Bootwicha, D. Panichakul, C. Kuhakarn, S. Prabpai, P. Kongsaeree, P. Tuchinda, V. Reutrakul, M. Pohmakotr, J. Org. Chem. 2009, 74, 3798-3805; o) W. Thaharn, T. Bootwicha, D. Soorukram, C. Kuhakarn, S. Prabpai, P. Kongsaeree, P. Tuchinda, V. Reutrakul, M. Pohmakotr, J. Org. Chem. 2012, 77, 8465-8479; p) V. Pharikronburee, T. Punirun, D. Soorukram, C. Kuhakarn, P. Tuchinda, V. Reutrakul, M. Pohmakotr, Org. Biomol. Chem. 2013, 11, 2022–2033; q) A. Chatupheeraphat, D. Soorukram, C. Ku-

a) L. Ojima (Ed.), Fluorine in Medicinal Chemistry and Chemical Biology, Blackwell, Oxford, UK, 2009; b) J.-P. Bégué, D. Bonnet-Delpon, Bioorganic and Medicinal Chemistry of Fluorine, John Wiley & Sons, New York, 2008; c) K. Miller, C. Fach, F. Diederich, Science 2007, 317, 1881–1886; d) P. Kirsch, Modern Fluoroorganic Chemistry, Wiley-VCH, Weinheim, Germany, 2004; e) T. Hiyama, Organofluorine Compounds: Chemistry and Applications, Springer, Berlin, 2000; f) V. A. Soloshonok (Ed.), Enantiocontrolled Synthesis of Fluoro-Organic Compounds: Stereochemical Challenges and Biomedicinal Targets, John Wiley & Sons, New York, 1999; g) J. T. Welch (Ed.), Selective Fluorination in Organic and Bioorganic Chemistry, American Chemical Society, Washington, DC, 1991.

 <sup>[2]</sup> a) I. Ruppert, K. Schlich, W. Volbach, *Tetrahedron Lett.* 1984, 25, 2195–2198; b) G. K. S. Prakash, R. Krishnamurti, G. A. Olah, *J. Am. Chem. Soc.* 1989, 111, 393–395; c) D. W. Nelson, J. Owens, D. Hiraldo, *J. Org. Chem.* 2001, 66, 2572–2582; d)

hakarn, P. Tuchinda, V. Reutrakul, C. Pakawatchai, S. Saithong, M. Pohmakotr, *Eur. J. Org. Chem.* **2013**, 6844–6858; r) K. Peewasan, C. Kuhakarn, D. Soorukram, P. Tuchinda, V. Reutrakul, M. Pohmakotr, *J. Fluorine Chem.* **2012**, *135*, 367– 372; s) F. Toulgoat, B. R. Langlois, M. Médebielle, J.-Y. Sanchez, *J. Org. Chem.* **2007**, *72*, 9046–9052.

- [5] a) K. I. Petko, L. M. Yagupol'skii, Russ. J. Org. Chem. 2004, 40, 601–602; b) J. Hine, J. J. Porter, J. Am. Chem. Soc. 1957, 79, 5493–5496.
- [6] M. Pohmakotr, W. Ieawsuwan, P. Tuchinda, P. Kongsaeree, S. Prabpai, V. Reutrakul, Org. Lett. 2004, 6, 4547–4550.
- [7] a) V. Reutrakul, V. Rukachaisirikul, *Tetrahedron Lett.* 1983, 24, 725–728; b) V. Reutrakul, T. Kruahong, M. Pohmaktor, *Tetrahedron Lett.* 1994, 35, 4851–4852; c) V. Reutrakul, T. Kruahong, M. Pohmakotr, *Tetrahedron Lett.* 1994, 35, 4853–4856.
- [8] L. Zhu, Y. Li, C. Ni, J. Hu, P. Beier, Y. Wang, G. K. S. Prakash, G. A. Olah, J. Fluorine Chem. 2007, 128, 1241–1247.
- [9] a) G. P. Stahly, J. Fluorine Chem. 1989, 43, 53–66; b) G. K. S. Prakash, J. Hu, Y. Wang, G. A. Olah, Eur. J. Org. Chem. 2005, 2218–2223; c) J. Hu, J. Fluorine Chem. 2009, 130, 1130–1139 and references cited; d) M. Hu, B. Gao, C. Ni, L. Zhang, J. Hu, J. Fluorine Chem. 2013, 155, 52–58.
- [10] M. Hu, F. Wang, Y. Zhao, Z. He, W. Zhang, J. Hu, J. Fluorine Chem. 2012, 135, 45–58.

- [11] R. Schwesinger, H. Schlemper, Angew. Chem. Int. Ed. Engl. 1987, 26, 1167–1169; Angew. Chem. 1987, 99, 1212.
- [12] a) H. Kawai, Z. Yuan, E. Tokunaga, N. Shibata, Org. Biomol. Chem. 2013, 11, 1446–1450; b) Y. Zhang, M. Fujiu, H. Serizawa, K. Mikami, J. Fluorine Chem. 2013, 156, 367–371.
- [13] Attempts to record <sup>19</sup>F NMR spectra of [PhSCF<sub>2</sub>]/[P<sub>4</sub>-*t*Bu/H]<sup>+</sup> (A) were made, according to a referee's suggestion. However, a mixture of PhSCF<sub>2</sub>H and P<sub>4</sub>-*t*Bu in non-deuterated dry THF with [D<sub>6</sub>]benzene as an internal standard showed no change in chemical shift of PhSCF<sub>2</sub>H in <sup>19</sup>F NMR analysis. However, upon addition of 2-naphthaldehyde to the mixture of PhSCF<sub>2</sub>H and P<sub>4</sub>-*t*Bu, the corresponding adduct **3a** was readily formed as observed in <sup>19</sup>F NMR analysis (see the Supporting Information). These observations are similar to those observed on <sup>19</sup>F NMR analysis of a mixture of CF<sub>3</sub>H and P<sub>4</sub>-*t*Bu reported by Mikami and co-workers; see ref.<sup>[12b]</sup>
- [14] K. Suzawa, M. Ueno, A. E. H. Wheatley, Y. Kondo, *Chem. Commun.* 2006, 4850–4852.
- [15] a) S. Shimizu, S. Shirakawa, T. Suzuki, Y. Sasaki, *Tetrahedron* 2001, 57, 6169–6173; b) T. Kobayashi, H. Kawate, H. Kakiuchi, H. Kato, *Bull. Chem. Soc. Jpn.* 1990, 63, 1937–1942.

Received: February 27, 2014 Published Online: May 20, 2014